Opdivo Success In Early Melanoma Paves Way For Other Tumor Types

Study finds that Bristol-Myers Squibb's PD-1 inhibitor Opdivo beats the company's CTLA-4 inhibitor Yervoy in Stage III/C or Stage IV melanoma, spurring hopes for ongoing studies in other tumor types.